SCHEMBL2559006

SCHEMBL2559006

COC(=O)c1ccc(-n2c(-c3cc(C)c(OCCO)c(C)c3)nc3ccccc3c2=O)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.61
ALDH1A1 P00352 8/20 0.50
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
TSHR P16473 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
BLM P54132 1/20 0.48
RAB9A P51151 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
MAPK1 P28482 2/20 0.47
G6PD P11413 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
KCNH2 Q12809 1/20 0.44
HRH3 Q9Y5N1 1/20 0.44
MAPT P10636 2/20 0.44
LMNA P02545 3/20 0.44
KDM4E B2RXH2 2/20 0.44
PLA2G1B P04054 2/20 0.44
ATG4B Q9Y4P1 2/20 0.44
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15512657 0.91 MAPK1 (0.57) POLBALDH1A1KMT2AMEN1TSHR
SCHEMBL2561941 0.86 ALDH1A1 (0.51) POLBALDH1A1KMT2AMEN1RAB9A
SCHEMBL2565658 0.86 SMN1; SMN2 (0.52) ALDH1A1KMT2AMEN1SMN1; SMN2RAB9A
SCHEMBL2566454 0.86 ALDH1A1 (0.51) ALDH1A1KMT2AMEN1RAB9ANPSR1
SCHEMBL2564148 0.86 ALDH1A1 (0.51) ALDH1A1KMT2AMEN1RAB9ANPSR1
SCHEMBL2562815 0.86 ALDH1A1 (0.51) ALDH1A1KMT2AMEN1RAB9ANPSR1
SCHEMBL2564925 0.86 KMT2A (0.50) POLBALDH1A1KMT2AMEN1TSHR
SCHEMBL2562510 0.85 ALDH1A1 (0.49) ALDH1A1KMT2AMEN1RAB9ANPSR1
SCHEMBL2565762 0.85 ALDH1A1 (0.49) ALDH1A1KMT2AMEN1RAB9ANPSR1
SCHEMBL2567691 0.85 ALDH1A1 (0.49) ALDH1A1KMT2AMEN1RAB9ANPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952021-B2 Compounds for the prevention and treatment of cardiovascular disease RESVERLOGIX CORP. (CA) 2015-02-10 US claimed
EP-2382194-B1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE RESVERLOGIX CORP (CA) 2014-03-12 EP claimed
US-20110294807-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE RESVERLOGIX CORP. (CA) 2011-12-01 US claimed
EP-2382194-A2 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE RESVERLOGIX CORP. (CA) 2011-11-02 EP claimed
WO-2010079431-A2 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE RESVERLOGIX CORP. (CA) 2010-07-15 WO claimed
WO-2015081284-A1 BIVALENT BROMODOMAIN LIGANDS, AND METHODS OF USING SAME COFERON, INC. (US) 2015-06-04 WO disclosed
WO-2015081280-A1 BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION COFERON, INC. (US) 2015-06-04 WO disclosed
EP-2660238-B1 Compounds for the prevention and treatment of cardiovascular disease RESVERLOGIX CORP (CA) 2015-05-06 EP disclosed
US-8952021-B2 Compounds for the prevention and treatment of cardiovascular disease RESVERLOGIX CORP. (CA) 2015-02-10 US disclosed
US-8952021-B2 Compounds for the prevention and treatment of cardiovascular disease RESVERLOGIX CORP. (CA) 2015-02-10 US disclosed
US-8952021-B2 Compounds for the prevention and treatment of cardiovascular disease RESVERLOGIX CORP. (CA) 2015-02-10 US disclosed
US-20140243286-A1 BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME COFERON, INC. (US) 2014-08-28 US disclosed
WO-2013033270-A2 BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME COFERON, INC. (US) 2013-03-07 WO disclosed
WO-2013033269-A1 BIOORTHOGONAL MONOMERS CAPABLE OF DIMERIZING AND TARGETING BROMODOMAINS AND METHODS OF USING SAME COFERON, INC. (US) 2013-03-07 WO disclosed
US-20110294807-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE RESVERLOGIX CORP. (CA) 2011-12-01 US disclosed
US-20110294807-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE RESVERLOGIX CORP. (CA) 2011-12-01 US disclosed
US-20110294807-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE RESVERLOGIX CORP. (CA) 2011-12-01 US disclosed
EP-2382194-A2 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE RESVERLOGIX CORP. (CA) 2011-11-02 EP disclosed
WO-2010079431-A2 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE RESVERLOGIX CORP. (CA) 2010-07-15 WO disclosed
WO-2010079431-A2 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE RESVERLOGIX CORP. (CA) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243286-A1 BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME BRDT, BRD4, BRD1 POLB 1252/4885ALDH1A1 4589/4885KMT2A 2014/4885
US-20110294807-A1 COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE APOB, APOL1, LDLR POLB 2021/4885ALDH1A1 355/4885KMT2A 4318/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.